# Context Therapeutics Inc.: overview

CNTX · Nasdaq · CIK 1842952 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cntx.md) · [Financials](/companies/cntx/financials.md) · [Filings](/companies/cntx/filings.md) · [Insiders](/companies/cntx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.22)](/filings/0001628280-25-049533.md) | not reported | [(0.05)](/filings/0001628280-26-031267.md) | [(0.09)](/filings/0001628280-26-053347.md) | [(0.10)](/filings/0001628280-25-049533.md) | not reported | [(0.09)](/filings/0001628280-26-031267.md) | [(0.15)](/filings/0001628280-26-053347.md) |
| Free cash flow | $m | [(1.9) d](/filings/0001628280-25-049533.md) | [(4.9) d](/filings/0001628280-26-020498.md) | [(5.1)](/filings/0001628280-26-031267.md) | [(5.8) d](/filings/0001628280-26-053347.md) | [(6.6) d](/filings/0001628280-25-049533.md) | [(8.9) d](/filings/0001628280-26-020498.md) | [(11.5)](/filings/0001628280-26-031267.md) | [(7.0) d](/filings/0001628280-26-053347.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(3.69)](/filings/0001842952-23-000041.md) | [(0.93)](/filings/0001842952-24-000011.md) | [(1.50)](/filings/0001842952-25-000028.md) | [(0.46)](/filings/0001628280-26-020498.md) | [(0.38)](/filings/0001628280-26-020498.md) |
| Free cash flow | $m | [(8.8)](/filings/0001842952-23-000041.md) | [(13.6)](/filings/0001842952-24-000011.md) | [(21.0)](/filings/0001842952-25-000028.md) | [(14.6)](/filings/0001628280-26-020498.md) | [(26.4)](/filings/0001628280-26-020498.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cntx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $4.1m | 7,419,355 |  | Unchanged |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $4.1m | 7,419,355 |  | Unchanged |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $3.9m | 7,063,141 |  | Added +100,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.4m | 6,169,250 |  | Added +5,322,554 |
| [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $2.8m | 4,998,267 |  | Unchanged |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $2.1m | 3,803,338 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.9m | 3,432,052 |  | Added +99 |
| [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $1.7m | 3,050,000 |  | Reduced −2,200,000 |
| [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $1.6m | 2,934,015 |  | Reduced −2,155,000 |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $1.5m | 2,682,696 |  | Unchanged |

## Recent filings

[All 304 filings](/companies/cntx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 16:16 ET | [8-K](/filings/0001628280-26-053378.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-053378 |
| 2026-08-05 | 16:09 ET | [10-Q](/filings/0001628280-26-053347.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053347 |
| 2026-07-31 | 16:08 ET | [8-K](/filings/0001628280-26-051399.md) | 3.01 Delisting notice | 0001628280-26-051399 |
| 2026-06-26 | 16:07 ET | [8-K](/filings/0001628280-26-045744.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-045744 |
| 2026-06-15 | 09:18 ET | [8-K](/filings/0001628280-26-043042.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-043042 |
| 2026-05-18 | 06:47 ET | [8-K](/filings/0001628280-26-035793.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-035793 |
| 2026-05-06 | 16:10 ET | [10-Q](/filings/0001628280-26-031267.md) | Quarterly report, period 2026-03-31 | 0001628280-26-031267 |
| 2026-05-01 | 16:07 ET | [8-K](/filings/0001628280-26-029323.md) | 8.01 Other events | 0001628280-26-029323 |
| 2026-04-28 | 16:12 ET | [DEF 14A](/filings/0001628280-26-027928.md) | Proxy statement, period 2026-04-28 | 0001628280-26-027928 |
| 2026-04-02 | 07:41 ET | [8-K](/filings/0001628280-26-022931.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-022931 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-020498.md), filed Mar 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1842952
- Tickers: CNTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.